Assignee
NOVIMMUNE SA
CH·48 granted patents·23 pending applications·454 citations·filing 1998–2024
Top patents by PatentIndex Score
71 records- 0198US7728114B2Anti-CD3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2005·Granted Jun 1, 2010·260 cites·25 claims
- 0293US8034344B2Anti-IL-6/IL-6R antibodies and methods of use thereofNOVIMMUNE SA·Filed 2009·Granted Oct 11, 2011·19 cites·6 claims
- 0393US7700098B2Anti-interferon gamma antibodies and methods of use thereofNOVIMMUNE SA·Filed 2006·Granted Apr 20, 2010·19 cites·9 claims
- 0493US7674884B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2005·Granted Mar 9, 2010·15 cites·3 claims
- 0592US9926382B2Methods for the generation of multispecific and multivalent antibodiesNOVIMMUNE SA·Filed 2013·Granted Mar 27, 2018·16 cites·12 claims
- 0691US7786268B2Anti-IP-10 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2008·Granted Aug 31, 2010·14 cites·11 claims
- 0791US7744884B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2007·Granted Jun 29, 2010·11 cites·12 claims
- 0890US10759862B2Anti-IL-6/IL-6R antibodies and methods of use thereofNOVIMMUNE SA·Filed 2017·Granted Sep 1, 2020·3 cites·6 claims
- 0989US12448444B2Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereofNOVIMMUNE SA·Filed 2022·Granted Oct 21, 2025·2 cites·35 claims
- 1089US11260117B2Anti-CD47 x anti-mesothelin antibodies and methods of use thereofNOVIMMUNE SA·Filed 2018·Granted Mar 1, 2022·4 cites·18 claims
- 1189US9682142B2Anti-interferon gamma antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jun 20, 2017·9 cites·10 claims
- 1289US7312320B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2004·Granted Dec 25, 2007·20 cites·14 claims
- 1388US9688755B2Fc receptor-binding polypeptides with modified effector functionsNOVIMMUNE SA·Filed 2013·Granted Jun 27, 2017·8 cites·7 claims
- 1486US10047144B2Methods of purifying antibodiesNOVIMMUNE SA·Filed 2012·Granted Aug 14, 2018·8 cites·8 claims
- 1585US9850304B2Anti-CD3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Dec 26, 2017·5 cites·3 claims
- 1684US9828430B2Anti-IL-6/IL-6R antibodiesNOVIMMUNE SA·Filed 2016·Granted Nov 28, 2017·3 cites·4 claims
- 1783US9234034B2Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodiesNOVIMMUNE SA·Filed 2012·Granted Jan 12, 2016·4 cites·5 claims
- 1881US10759858B2Anti-CD3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2017·Granted Sep 1, 2020·1 cites·14 claims
- 1980US10457749B2Methods of purifying bispecific antibodiesNOVIMMUNE SA·Filed 2016·Granted Oct 29, 2019·4 cites·16 claims
- 2078US11203646B2Anti-CD3 epsilon antibodies and methods of use thereofNOVIMMUNE SA·Filed 2019·Granted Dec 21, 2021·1 cites·24 claims
- 2178US10689441B2Anti—TLR4 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2014·Granted Jun 23, 2020·4 cites·19 claims
- 2278US10597465B2Methods for the generation of multispecific and multivalent antibodiesNOVIMMUNE SA·Filed 2017·Granted Mar 24, 2020·1 cites·5 claims
- 2378US10023646B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2017·Granted Jul 17, 2018·1 cites·8 claims
- 2478US2024400720A1Anti-cd47 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2024·Application pending·0 cites
- 2576US9540444B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jan 10, 2017·1 cites·6 claims
- 2675US10556960B2Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkersNOVIMMUNE SA·Filed 2017·Granted Feb 11, 2020·2 cites·18 claims
- 2774US11613582B2Anti-IL-6/IL-6R antibodies and methods of use thereofNOVIMMUNE SA·Filed 2020·Granted Mar 28, 2023·0 cites·2 claims
- 2874US10421809B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2016·Granted Sep 24, 2019·2 cites·8 claims
- 2974US10400044B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2016·Granted Sep 3, 2019·1 cites·17 claims
- 3074US9512221B2Anti-TLR4 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2014·Granted Dec 6, 2016·3 cites·6 claims
- 3174US2022324994A1Anti-tlr4 antibodies and uses thereofNOVIMMUNE SA·Filed 2021·Application pending·0 cites
- 3273US11059910B2Anti-CD47 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jul 13, 2021·1 cites·7 claims
- 3372US9815909B2Readily isolated bispecific antibodies with native immunoglobulin formatNOVIMMUNE SA·Filed 2013·Granted Nov 14, 2017·1 cites·10 claims
- 3472US9650437B2Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodiesNOVIMMUNE SA·Filed 2013·Granted May 16, 2017·1 cites·20 claims
- 3572US9475873B2Nucleic acids encoding anti-IL-17F antibodies and methods of use thereofNOVIMMUNE SA·Filed 2014·Granted Oct 25, 2016·1 cites·13 claims
- 3672US9453076B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2013·Granted Sep 27, 2016·1 cites·13 claims
- 3772US6800469B1Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigensNOVIMMUNE SA·Filed 2000·Granted Oct 5, 2004·5 cites·4 claims
- 3871US2021009691A1Anti-cd3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2020·Application pending·0 cites
- 3970US10982004B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2019·Granted Apr 20, 2021·0 cites·11 claims
- 4070US2025171537A1Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodiesNOVIMMUNE SA·Filed 2024·Application pending·0 cites
- 4169US10844132B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2018·Granted Nov 24, 2020·0 cites·8 claims
- 4268US9688769B2Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkersNOVIMMUNE SA·Filed 2014·Granted Jun 27, 2017·2 cites·18 claims
- 4364US9534049B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jan 3, 2017·0 cites·10 claims
- 4464US2020231707A1Readily isolated bispecific antibodies with native immunoglobulin formatNOVIMMUNE SA·Filed 2019·Application pending·0 cites
- 4563US11840553B2Anti-CD47 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2018·Granted Dec 12, 2023·0 cites·2 claims
- 4663US2024254223A1Reciprocally masked antibody-cytokine fusion proteins and methods of use thereofNOVIMMUNE SA·Filed 2023·Application pending·0 cites
- 4762US2020239566A1Anti-tlr4 antibodies and uses thereofNOVIMMUNE SA·Filed 2019·Application pending·0 cites
- 4861US10494446B2Readily isolated bispecific antibodies with native immunoglobulin formatNOVIMMUNE SA·Filed 2017·Granted Dec 3, 2019·0 cites·7 claims
- 4961US2025075000A1Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activityNOVIMMUNE SA·Filed 2024·Application pending·0 cites
- 5060US2023295348A1Composition and methods for the selective activation of cytokine signaling pathwaysNOVIMMUNE SA·Filed 2023·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →